Compass Therapeutics (CMPX) Short term Debt (2019 - 2021)

Compass Therapeutics (CMPX) has 3 years of Short term Debt data on file, last reported at $3.7 million in Q3 2021.

• For the quarter ending Q3 2021, Short term Debt fell 49.82% year-over-year to $3.7 million; the trailing twelve-month figure through Sep 2021 stood at $3.7 million (down 49.82% YoY), and the FY2020 full-year result was $7.5 million, up 33.91% from the prior year.
• Short term Debt eased to $3.7 million in Q3 2021, from $7.5 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $7.5 million in Q1 2021 to a low of $3.7 million in Q3 2021.
• A 3-year average of $6.5 million and a median of $7.5 million in 2020 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt jumped 33.91% in 2020 and tumbled 49.82% in 2021, its largest moves.
• Tracing CMPX's Short term Debt over 3 years: stood at $5.6 million in 2019, then jumped by 33.91% to $7.5 million in 2020, then tumbled by 49.86% to $3.7 million in 2021.
• Business Quant data shows CMPX's Short term Debt at $3.7 million in Q3 2021, $7.5 million in Q1 2021, and $7.5 million in Q4 2020.